Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients (NCT04943224) | Clinical Trial Compass
RecruitingPhase 2
Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients
Poland12 participantsStarted 2021-04-01
Plain-language summary
Prospective, interventional, open, randomized, single-center, non-commercial clinical trial to optimize treatment and dosage of trametinib in juvenile patients with histiocytosis resistant to conventional therapy and without the BRAF gene mutation or after the failure of vemurafenib treatment.
Who can participate
Age range1 Year – 18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Lack of mutations in the BRAF gene in tumor tissues and/or circulating tumor DNA (ctDNA) at any stage of treatment or follow-up, or failure of Vemurafenib treatment in BRAF positive patients.
✓. Failure of the treatment (at least one of below needs to apply in order for this requirement to be satisfied):
✓. Progression on the I and/or II line treatment, including at least one risk organ; prior treatment should include a minimum of 6 weeks of weekly Vinblastine with a minimum of 28 days prednisolone or minimum 2 cycles of Cytosine Arabinoside in 4-day cycles and/or Cladribine in 5-day cycles as a 2nd line treatment, minimum 2 cycles, or other second-line treatment or
✓. Disease reactivation after an initial response to treatment with Vimblastine and prednisolone as the first line and/or no response to second line treatment using one of two drugs: Cytosine Arabinoside in 4- day cycles and/or Cladribine in 5-day cycles, minimum 2 cycles, or other I/ II line treatment or occurrence of involvement of at least one risk organ or
✓. Signing of informed consent for trial participation (including for Trametinib treatment) according with current legal regulations.
✓. Consent to the use of effective contraception throughout the Trametinib administration period and a minimum of 1 year after discontinuation in patients at puberty and sexual maturity.
. Hypersensitivity to the study drug or any of its ingredients.
✕. Iritis, uveitis, obstruction of the retinal veins.
✕. Simultaneous treatment with other drugs which might interact with Trametinib.
✕. Persistent toxicity related to prior therapy, making it impossible to treat with Trametinib.
✕. Diagnosis of other malignancies before study inclusion.
✕. Other acute or persistent disorders, behaviors or abnormal laboratory test results, which might increase the risk related to the participation in this clinical trial or to taking the study drug, or which might influence the interpretation of the study results, or which, in the investigator's opinion, disqualify a patient from participating in the trial.